LSX 世界大會在里斯本圓滿落幕，聚焦生物技術投資
LSX World Congress Concludes in Lisbon Focusing on Biotech Investment
2026年LSX歐洲世界大會近期於里斯本圓滿落幕，標誌著生命科學領域的關鍵時刻。
The LSX World Congress Europe 2026 recently concluded in Lisbon, marking a pivotal moment for the life sciences sector.
該大會於3月25日至26日舉行，是生物技術、醫療技術和數位健康領域的投資者與早期企業的核心樞紐。
Held from March 25–26, the congress served as a central hub for investors and early-stage companies in biotech, medtech, and digital health.
活動聚焦於種子輪至B輪融資的企業，旨在彌合創新差距，協助研究成果邁向商業成功。
By focusing on seed-to-Series B firms, the event aimed to bridge the innovation gap, helping research reach commercial success.
大會的一大亮點是「春季創新週」，當時大會與BIO-Europe Spring連續舉行。
A major highlight was the 'Spring Innovation Week,' where the congress was held back-to-back with BIO-Europe Spring.
此外，如瓦隆地區等區域代表團也藉由此次大會向全球受眾展示其獨特的創新成果。
Furthermore, regional delegations, such as those from Wallonia, leveraged the congress to showcase niche innovations to a global audience.
在產業應對複雜的衰退後融資環境之際，里斯本大會發揮了至關重要的市場風向指標作用，證實儘管市場面臨挑戰，對於高潛力創新的需求依然強勁。
As the industry navigates a complex post-downturn funding environment, the Lisbon congress acted as a vital pulse-check, confirming that despite market challenges, the appetite for high-potential innovation remains strong.
此次專業領域的匯聚，進一步鞏固了里斯本作為歐洲生命科學資本關鍵目的地的地位。
This convergence of expertise reinforces Lisbon's position as a key destination for European life science capital.
